Literature DB >> 2105793

Recurrent spontaneous abortion and polycystic ovarian disease: comparison of two regimens to induce ovulation.

P Johnson1, J M Pearce.   

Abstract

OBJECTIVE: To determine whether pituitary suppression before induction of ovulation reduces the rate of spontaneous abortion in women with polycystic ovarian disease and primary recurrent spontaneous abortions.
DESIGN: Closed, randomised, sequential trial. Pairs of women were allocated to each treatment by the toss of a coin.
SETTING: Supraregional clinic for women who had had recurrent spontaneous abortions.
SUBJECTS: Forty two women with polycystic ovarian disease and primary recurrent spontaneous abortions.
INTERVENTIONS: Ovulation was induced by clomiphene or pituitary suppression with buserelin followed by pure follicle stimulating hormone. MAIN OUTCOME MEASURES: Preference for a particular treatment was noted. A preference occurred when one woman in a pair had a successful pregnancy (defined as one of over 12 weeks' gestation) and one had a spontaneous abortion; the preference was for the treatment resulting in the successful pregnancy.
RESULTS: Spontaneous abortions occurred in 11 of 20 women given clomiphene compared with two of 20 who had pituitary suppression. Eleven preferences were found for buserelin and two for clomiphene. In seven pairs both women had successful pregnancies. One pair was discarded because one of the women did not become pregnant. The ratio of luteinising hormone concentration to follicular diameter was found to be a possible diagnostic indicator of spontaneous abortion.
CONCLUSION: Pituitary suppression before induction of ovulation significantly reduces the risk of spontaneous abortion in women with polycystic ovarian disease and primary recurrent spontaneous abortions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2105793      PMCID: PMC1662188          DOI: 10.1136/bmj.300.6718.154

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  4 in total

1.  Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism.

Authors:  J Adams; D W Polson; S Franks
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-09

2.  Further clinical experience with clomiphene citrate.

Authors:  A H Macgregor; J E Johnson; C A Bunde
Journal:  Fertil Steril       Date:  1968 Jul-Aug       Impact factor: 7.329

3.  Evidence for a hypothalamic site of action of clomiphene citrate in women.

Authors:  J F Kerin; J H Liu; G Phillipou; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1985-08       Impact factor: 5.958

4.  Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome.

Authors:  R Homburg; N A Armar; A Eshel; J Adams; H S Jacobs
Journal:  BMJ       Date:  1988-10-22
  4 in total
  6 in total

1.  Recurrent miscarriage.

Authors:  L Regan
Journal:  BMJ       Date:  1991-03-09

Review 2.  The significance of high follicular-phase luteinizing hormone levels in the treatment of women with polycystic ovarian syndrome by in vitro fertilization.

Authors:  B C Tarlatzis; G Grimbizis
Journal:  J Assist Reprod Genet       Date:  1997-01       Impact factor: 3.412

3.  Recurrent spontaneous abortion and polycystic ovarian disease: comparison of two regimens to induce ovulation.

Authors: 
Journal:  BMJ       Date:  1995-07-22

4.  Infertility treatment in Poland.

Authors:  M Szamatowicz; D Grochowski
Journal:  J Assist Reprod Genet       Date:  1994-04       Impact factor: 3.412

5.  Inadvertent exposure of early pregnancy to gonadotropin releasing hormone analogue.

Authors:  A Shulman; M Shilon; C Bahary; J Dor; A Ellenbogen; S Mashiach
Journal:  J Assist Reprod Genet       Date:  1993-07       Impact factor: 3.412

6.  Effects of a gonadotropin releasing hormone agonist on oocyte maturation, fertilization, and embryonal development of mice.

Authors:  B C Yang; T Uemura; H Minaguchi
Journal:  J Assist Reprod Genet       Date:  1995-11       Impact factor: 3.412

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.